Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
On February 9, 2026,
NeuroSense Therapeutics Ltd. issued a press release reporting that it is expanding its global intellectual property protection strategy
with the grant of an Australian patent covering the PrimeC composition. A copy of the press release is furnished herewith as Exhibit 99.1.
This Report on Form 6-K
(other than the third paragraph in Exhibit 99.1) is hereby incorporated by reference into the registrant’s Registration Statements
on Form S-8 (File No. 333-262480
and 333-289658) and Form
F-3 (File No. 333-269306,
333-260338, 333-283656,
333-284051, 333-291122
and 333-293060) to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports
subsequently filed or furnished.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Exhibit 99.1
NeuroSense Expands Global IP Protection Strategy
With Granted Australian Patent Covering PrimeC Composition
Strengthens Global IP Portfolio for PrimeC Through
2042
CAMBRIDGE, Mass., Feb. 9, 2026 /PRNewswire/
-- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”),
a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that
the Australian Patent Office (IP Australia) has granted Australian Patent No. 2022370513, entitled “Compositions
Comprising Ciprofloxacin and Celecoxib,” representing another strategic step in the continued expansion of the Company’s
global intellectual property protection for PrimeC.
The granted Australian patent, following prior
approval of the corresponding U.S. patent (12,097,185), further expands NeuroSense’s patent protection across key global markets
and reinforces the Company’s exclusivity strategy for PrimeC, with patent coverage extending through October 2042. NeuroSense continues
to strengthen the company’s global intellectual property estate and to support the long-term development and potential commercialization
of PrimeC in ALS, Alzheimer’s disease and other neurodegenerative indications.
“Securing patent protection in Australia,
in addition to the already granted patent in the US, is an important step in executing our global IP protection strategy for PrimeC,”
said Alon Ben-Noon, Chief Executive Officer of NeuroSense. “As we advance PrimeC toward pivotal development and potential commercialization,
building a broad, durable IP estate across major jurisdictions is central to supporting long-term value creation.”
PrimeC is a proprietary fixed-dose oral therapy
combining ciprofloxacin and celecoxib in a synchronized, extended-release formulation specifically engineered to deliver both agents in
a coordinated manner - a key differentiator versus simple co-administration. The formulation enables consistent exposure across multiple
disease pathways implicated in ALS, including neuroinflammation, iron dysregulation, and miRNA dysregulation, supporting a multi-target
disease-modifying approach.
PrimeC is Phase 3-ready in ALS, following positive
Phase 2b PARADIGM results and FDA clearance of the pivotal Phase 3 protocol.
About
NeuroSense
NeuroSense
Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from
debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS),
Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with
limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on
strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple
pathways associated with these diseases.
For additional
information, we invite you to visit our website and
follow us on LinkedIn,
YouTube and X.
Information that may be important to investors may be routinely posted on our website and these social media channels.
About
PrimeC
PrimeC,
NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved
drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute
to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit
the progression of ALS and AD.
About
ALS
Amyotrophic
lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years
from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1
billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.
About Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting
more than 30 million people globally. AD is characterized by memory loss, cognitive decline, and behavioral changes, and currently has
no cure. Existing therapies provide only limited symptomatic relief, leaving a significant unmet need for disease-modifying treatments
that can slow or halt progression. Given the complexity of AD, approaches that target multiple disease mechanisms simultaneously, such
as PrimeC, hold potential to deliver meaningful therapeutic advances for patients and their families.
Forward-Looking
Statements
This press
release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other
than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained
in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,”
“could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,”
“plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,”
“will” “would,” or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject
to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory
filings, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding the length of
patent coverage, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not
occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These
risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data, including
from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed
on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC).
You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting
NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange
Commission on April 7, 2025 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement
are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
For further
information: Email: info@neurosense-tx.com, Tel: +972 (0)9 799 6183
